Quick Summary
- First-quarter EPS reached $1.15, aligning with Wall Street projections of $1.14–$1.15
- Quarterly revenue totaled $11.16B, surpassing the $11B forecast
- The Exact Sciences acquisition strengthened the cancer diagnostics segment
- Medical devices, the company’s biggest revenue generator, maintained strong momentum
- Second-quarter EPS outlook of $1.25–$1.31 trails the $1.32 analyst projection
Abbott Laboratories delivered first-quarter financial results on April 16 that topped Wall Street’s revenue projections, with the recently completed cancer diagnostics acquisition providing meaningful support.
The healthcare giant posted adjusted earnings per share of $1.15 for the period. This figure aligned with one estimate of $1.15 and exceeded another consensus calculation of $1.14, varying by data provider.
Quarterly revenue reached $11.16 billion, surpassing the $11 billion analyst forecast.
Shares finished trading at $101.56 before the earnings announcement. ABT has declined 16.59% during the previous three months and fallen 22.46% year-over-year.
The Exact Sciences transaction influenced these quarterly figures. Abbott announced plans to acquire the cancer-testing company in November at $105 per share, representing a transaction valued at approximately $23 billion. The purchase finalized in March 2026.
This transaction represented among Abbott’s most significant acquisitions and signaled an expansion into cancer diagnostics. Performance from this division supported the Q1 revenue outperformance.
Device Segment Maintains Momentum
Abbott’s medical device division continues as its primary revenue source. The segment posted solid results in Q1, contributing to the overall revenue beat.
The organization has relied on its device operations as a fundamental revenue engine across recent quarters. This pattern persisted throughout the opening months of 2026.
Forward Outlook Falls Short of Analyst Targets
For the second quarter of 2026, Abbott projected EPS between $1.25 and $1.31. Wall Street’s consensus estimate stood at $1.32, placing Abbott’s midpoint slightly under analyst expectations.
For the complete fiscal year, Abbott forecasts EPS ranging from $5.38 to $5.58. The analyst consensus of $5.47 lands within this projected range.
Abbott recorded zero positive EPS estimate revisions alongside 18 negative revisions during the past 90 days. This represents a change from the previous quarter’s “great performance” financial health assessment — InvestingPro currently assigns Abbott a “good performance” financial health rating.
The revenue outperformance provides some confidence, despite guidance falling marginally short of expectations. Abbott’s Q1 top-line results emerged as the stronger element of this quarterly report.
The full-year EPS consensus of $5.47 remains within Abbott’s projected range of $5.38 to $5.58, providing the company opportunity to meet or exceed that benchmark throughout the remainder of the year.
